Sourcing & Procurement

  • Report – AMFM Phase 1 Independent Evaluation

    The Global Fund to Fight AIDS, Tuberculosis and Malaria made public the final report of an independent evaluation of the pilot phase of the Affordable Medicines Facility–malaria, also known as AMFm, on 4 October 2012.

    The Global Fund commissioned the independent evaluation to assess the extent to which AMFm achieved the main objectives laid out for its pilot phase, which ended in December 2012. The independent evaluation was mandated by the Global Fund Board. The final report is now available Affordable Medicines Facility-malaria (AMFm) Phase 1 Independent Evaluation. This report is an update to the preliminary report that was released in July 2012.

    The goal of AMFm was to improve access to artemisinin-based combination therapies (ACTs), the most effective anti-malaria treatment. The AMFm pilot phase was launched in April 2009 and began operations in July 2010. It set out to increase availability, particularly through private outlets where most people seek their treatments, and drive down the price of ACTs through a factory-gate global subsidy of ACTs combined with country-level measures to support its implementation.

    The AMFm pilot phase operated in eight countries: Cambodia, Ghana, Kenya, Madagascar, Niger, Nigeria, Tanzania, and Uganda. The independent evaluation assessed the program in each of the pilot countries that was operational at the time of the endline survey.

    By the end of Phase 1 on 31 December 2012, AMFm had subsidized over 340 million ACT treatments. This initial global subsidy for AMFm Phase 1 was financed through contributions from UNITAID, the governments of the United Kingdom and Canada, and the Bill & Melinda Gates Foundation. Technical support was provided by members of the Roll Back Malaria Partnership.

    The following key events led to the start of AMFm Phase 1:

      • 2004 - IOM Report Saving Lives, Buying Time
        Global-level subsidy for ACTs an urgent “global public good” to address increased ineffectiveness of widely available treatment, risk posed by oral artemisinin monotherapies and the high cost of ACTs
      • 2006 - RBM Partnership fostered multi-institutional process
      • 2007 - AMFm Technical Design approved by RBM Board -
        Included the addition of “supporting interventions” to promote the appropriate use of ACTs

    AMFm Transition

    Following the implementation and Independent Evaluation of AMFm Phase 1:- In November 2012 the Global Fund Board decided to modify the existing AMFm business line by integrating lessons learned from Phase 1 into Global Fund core grant management and financial processes. The AMFm was subsequently renamed the Private Sector Co-payment Mechanism.

    Regarding Contributors: UNITAID, DFID, CIDA and the Bill & Melinda Gates Foundation contributed an additional US$ 125 million for ACT co-payments for Phase 1 countries to transition during 2013, to other funding sources. In 2014, DFID contributed yet an additional 64 million GBP (pounds sterling) to support Kenya, Nigeria and Uganda’s transitions to the Private Sector Co-payment Mechanism.

    Cambodia, Niger and Zanzibar, each for different reasons, stopped implementation of the AMFm after the pilot (see the Independent Evaluation report). As at quarter 2, in 2014, Ghana, Madagascar and Tanzania have integrated the Private Sector Co-payment Mechanism into existing Global Fund grants.